Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

被引：0
|
作者：
Laura M. Spring
Hyo Han
Minetta C. Liu
Erika Hamilton
Hanna Irie
Cesar A. Santa-Maria
James Reeves
Peng Pan
Ming Shan
Yongqiang Tang
Julie R. Graham
Sebastien Hazard
Leif W. Ellisen
Steven J. Isakoff
机构：
[1] Massachusetts General Hospital and Harvard Medical School,Translational Discovery & Development
[2] Moffitt Cancer Center-McKinley Outpatient Clinic,undefined
[3] Mayo Clinic,undefined
[4] Sarah Cannon Research Institute/Tennessee Oncology,undefined
[5] Icahn School of Medicine at Mount Sinai,undefined
[6] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[7] Florida Cancer Specialists-South/Sarah Cannon Research Institute,undefined
[8] GSK,undefined
[9] Ludwig Center at Harvard,undefined
[10] EQRx,undefined
[11] Boston Pharmaceuticals,undefined
[12] Alkermes Incorporated,undefined
[13] Bicycle Therapeutics,undefined
来源：
Nature Cancer | 2022年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1138 / 1138
相关论文
共 50 条
  • [21] Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer
    Han, H.
    Hamilton, E.
    Irie, H.
    Isakoff, S.
    Jelovac, D.
    Liem, A.
    Liu, M. C.
    Milillo, A.
    Nangia, J.
    Page, D.
    Reeves, J.
    Santa-Maria, C.
    Duncan, M.
    Graham, J. R.
    Chen, J.
    Dezube, B. J.
    Spring, L.
    CANCER RESEARCH, 2019, 79 (04)
  • [22] Veliparib, Carboplatin, and Paclitaxel in Patients with BRCA-mutated Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (01)
  • [23] Fertility and pregnancy issues in BRCA-mutated breast cancer patients
    Lambertini, Matteo
    Goldrat, Oranite
    Toss, Angela
    Azim, Hatem A., Jr.
    Peccatori, Fedro A.
    Ignatiadis, Michail
    Del Mastro, Lucia
    Demeestere, Isabelle
    CANCER TREATMENT REVIEWS, 2017, 59 : 61 - 70
  • [24] Niraparib Efficacy and Safety in Patients With BRCA-Mutated Ovarian Cancer: Results From Three Phase 3 Niraparib Trials
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 7 - 8
  • [25] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis
    Balmana, J.
    Fasching, P. A.
    Delaloge, S.
    Park, Y. H.
    Eisen, A.
    Bourgeois, H.
    Kemp, Z.
    Jankowski, T.
    Sohn, J.
    Aksoy, S.
    Timcheva, C. V.
    Park-Simon, T-W.
    Torres, A. Anton
    John, E.
    Baria, K.
    Walker, G.
    Gelmon, K. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S205 - S206
  • [26] An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)
    Domchek, Susan M.
    Postel-Vinay, Sophie
    Bang, Yung-Jue
    Park, Yeonh H.
    Alexandre, Jerome
    Delord, Jean-Pierre
    Italiano, Antoine
    You, Benoit
    Bastian, Sara
    Krebs, Matthew
    Wang, Ding
    Waqar, Saiama
    Angell, Helen
    Learoyd, Maria
    Chang, Shao-Chun
    Gresty, Christopher
    Herbolsheimer, Pia
    Kaufman, Bella
    CANCER RESEARCH, 2018, 78 (04)
  • [27] Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context
    Gonzalez-Martin, Antonio
    Matulonis, Ursula A.
    Korach, Jacob
    Mirza, Mansoor R.
    Moore, Kathleen N.
    Wu, Xiaohua
    York, Whitney
    Gupta, Divya
    Lechpammer, Stanislav
    Monk, Bradley J.
    FUTURE ONCOLOGY, 2022, 18 (23) : 2505 - 2536
  • [28] Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients
    Angell, Helen
    Ros, Vidalba Rocher
    Standifer, Nathan
    Lai, Zhongwu
    Gresty, Christopher
    Delord, Jean-Pierre
    De Jonge, Maja
    Postel-Vinay, Sophie
    Italiano, Antoine
    Krebs, Matthew G.
    Kaufman, Bella
    Park, Yeon Hee
    Domchek, Susan
    Herbolsheimer, Pia
    Hodgson, Darren
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [29] Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer
    Garber, Haven
    Raghavendra, Akshara Singareeka
    Hess, Kenneth R.
    Arun, Banu
    Ibrahim, Nuhad K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Niraparib efficacy and safety in patients with BRCA-mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials
    Banerjee, Ashish
    Gonzalez-Martin, Antonio
    Matulonis, Ursula
    Korach, Jacob
    Mirza, Mansoor R.
    Moore, Kathleen
    Gupta, Divya
    Lechpammer, Stanislav
    Monk, Bradley J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 116 - 117
12345